Date / Time
The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with pancreatic cancer.
This program is intended for medical oncologists and other healthcare providers who care for patients with pancreatic cancer globally.
Upon completion of this activity, participants should be able to:
- Evaluate the clinical rationale for assessing BRCA1/2 and other DNA damage repair gene alterations in pancreatic cancer
- Plan therapeutic strategies for patients with pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
- Examine the emerging role of PARP inhibitors in the frontline maintenance setting for patients with BRCA-mutant pancreatic cancer
- Discuss the rationale for using platinum-based chemotherapy in patients newly diagnosed pancreatic cancer and germline BRCA mutations, based on available data and treatment guidelines